

Citius Pharmaceuticals, Inc.

(NASDAQ: CTXR)

GCFF Virtual Conference 2023– Healthcare (Asia Pacific) /
2023年GCFF线上投资会议 – 医疗保健投资(亚太专场)
NOVEMBER 29, 2023 / 2023年11月29日

FORWARD-LOOKING STATEMENTS / 前瞻性声明

This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. The information contained in this presentation and the comments and remarks of the representatives of the Company made during any presentation to which this presentation relates are integrally related and, as such, are intended to be delivered and understood together. Information provided in this presentation speaks only as of the date hereof. The Company assumes no obligation to update any statement after the date of this presentation as a result of new information, subsequent events or any other circumstances.

This presentation also includes express and implied forward-looking statements regarding the current expectations, estimates, opinions and beliefs of the Company that are not historical facts. Such forward-looking statements may be identified by words such as "believes", "expects", "endeavors", "anticipates", "intends", "plans", "estimates", "projects", "should", "objective" and variations of such words and similar words. The accuracy of such statements is dependent upon future events, and involves known and unknown risks, uncertainties and other factors beyond the Company's control that may cause actual results to differ materially from what is presented herein. Investors are strongly encouraged to carefully review the Company's SEC filings for a listing of the risks that could cause actual results to differ from these forward looking statements. These forward-looking statements speak only as of the date of this presentation and should not be construed as statements of facts.

INVESTMENT HIGHLIGHTS / 投资亮点

1 Diversified Pipeline: Building a Biotech Platform / 多元化的管线：搭建一个生物科技平台

- LYMPHIR™: purified reformulation of IL-2 diphtheria toxin fusion protein for CTCL[1] **(P3 completed)** /用于 CTCL 的 IL-2 白喉毒素融合蛋白的纯化新制剂（ **P3已完成**）
- Mino-Lok®: potential to be **first and only** FDA-approved product to salvage infected CVCs causing CLABSI **(P3)** / 有潜力成为**首个且唯一一个**获得 FDA 批准用于抢救导致 CLABSI 的感染 CVC的产品**(P3)**
- Halo-Lido: potential to be **first and only** FDA-approved Rx therapy for hemorrhoids **(P2b completed)** / 有潜力成为**首个且唯一一个**获得 FDA 批准的痔疮Rx疗法（ **P2b已完成**）

2 Attractive Multi-billion $ Global Market Opportunities / 几十亿规模的诱人全球市场机会

- CTCL market est. $300-$400+M with larger potential in PTCL and immuno-oncology (I/O) / CTCL市场规模估计为 $3-4 亿以上，在 PTCL 和免疫肿瘤学领域(I/O)潜力更大
- CRBSI/CLABSI market est. >$1.8B worldwide / 全球CRBSI/CLABSI市场规模预计超过$18亿
- Rx hemorrhoid market est. >$2B US / 美国Rx痔疮市场规模预计超过$20亿

3 Healthy Financial Platform / 健康的财务平台

- $33.3 M cash as of 6/30/23 with runway through August 2024 / 截止2023年6月30日拥有现金$3330万，可以用到2024年8月
- $15 million registered direct offering May 2023 / 2023年5月注册直接发行获得$1500万
- Complete Response Letter (CRL) remediation efforts not expected to impact cash runway / 完整回应函(CRL) 的补救工作预计不会影响现金消耗
- $26.5 million invested by insiders / 内部人士投资$2650万

3 Anticipated Value Driving Catalysts / 预期价值驱动催化剂

- Completion of Mino-Lok Phase 3 trial; topline results expected first half of 2024 / 完成Mino-Lok的3期试验，顶线结果预计2024年上半年发布
- Resubmission of LYMPHIR planned for early 2024 / 计划2024年初重新提交LYMPHIR

1. LYMPHIR™ has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed brand name for I/ONTAK (E7777). /美国食品药品监督管理局(FDA) 已有条件地接受 LYMPHIRTM 作为 I/ONTAK (E7777) 的拟议品牌名称。

MANAGEMENT TEAM WITH PROVEN TRACK RECORD
拥有成功履历的管理团队

LEONARD MAZUR
CHAIRMAN, CEO & CO-FOUNDER
董事会主席、首席执行官与联合创始人

MYRON HOLUBIAK
VICE CHAIRMAN & CO-FOUNDER
董事会副主席与联合创始人

JAIME BARTUSHAK
EVP, CFO & CBO
资深副总裁、首席财务官与首席品牌官

DR. MYRON CZUCZMAN
EVP, CHIEF MEDICAL OFFICER
资深副总裁、首席医学官



GARY TALARICO
EVP, OPERATIONS
资深运营副总裁

KELLY CREIGHTON
EVP, CMC
资深CMC副总裁

CATHERINE KESSLER
EVP, REGULATORY AFFAIRS
资深法规事务副总裁

NIK BURLEW
EVP, QUALITY ASSURANCE
资深质量保证副总裁

JAY WADEKAR
SVP, BUSINESS STRATEGY
资深商业策略副总裁

DR. ALAN LADER
SVP, CLINICAL OPERATIONS
资深临床运营副总裁

MILESTONES & RECENT DEVELOPMENTS / 里程碑与最近发展

	2021	2022	2023	2024
LYMPHIR	Q4: Phase 3 Clinical Trial Completed / 第四季度：三期临床试验已完成	Q3: Filed BLA / 第三季度：提交BLA	• July 28: CRL / 7月28日：CRL • Citius addressing enhanced product testing required by FDA / Citius解决FDA要求的增强产品测试 • No clinical data issues related to safety or efficacy / 没有与安全性或有效性相关的临床数据问题 • Citius planning for resubmission / Citius计划重新提交	Early 2024: resubmission planned / 2024年初：计划重新提交
MINO-LOK		Expanded trial to sites in India / 将试验扩展到印度的站点	• 92 required events achieved for trial completion, subject to confirmation by independent reviewers / 完成试验所需的92项事件，须经独立审稿人确认 • Patients in active treatment may result in additional events / 正在接受积极治疗的患者可能会发生其他事件 • Trial to continue enrolling in near term / 试验近期继续招募患者	First half 2024: topline results anticipated / 2024年上半年：预计发布顶线结果
HALO-LIDO			• Phase 2b trial enrollment completed April 2023 / 2023年4月完成了2b试验患者招募 • Positive Phase 2b results reported / 已报告了2b期试验结果 • Preparations underway for end of Phase 2 meeting with FDA / 正在筹备与 FDA 的二期试验结束的会议	

MINO-LOK

Phase 3 / 三期

LATE-STAGE PRODUCT CANDIDATE: MINO-LOK
后期产品： MINO-LOK

First and Only antibiotic lock therapy under investigation to sterilize and salvage infected Central Venous Catheters (CVCs) / 首个也是唯一一个正在研究中的抗生素封管疗法，用于消毒和挽救受感染的中心静脉导管(CVC)

7 Million / 700万

Central Venus Catheters (CVCs) used annually in the U.S. * / 美国每年使用中心静脉导管(CVCs) *

4 Million / 400万

Long-term CVCs (>1 month) in the U.S. / 美国长期CVCs（1个月以上）

~500,000

CRBSI/CLABSI infections annually in the U.S. ** / 美国每年CRBSI/CLABSI感染**

12-25%

CRBSI/CLABSI associated mortality & morbidity / 与CRBSI ** / CLABSI相关的死亡率与发病率**

* Shah H., Bosch W., Hellinger W. C., Thompson K. M. (2013). Intravascular catheter-related bloodstream infection. Neurohospitalist 3, 144–151. doi: 10.1177/1941874413476043.

** Antoňáková Němčíková A, Bednárovská E. Catheter-related bloodstream infections: do we know all of it? Klin Onkol. 2017;30(6):405–411. doi: 10.14735/amko2017405.

CURRENT STANDARD OF CARE IS A POOR OPTION
目前的治疗标准是一个糟糕的选择

Multiple challenges to removing and replacing infected CVCs / 移除和替换感染的CVCs面临多个挑战

- Limited availability of other vascular sites / 其他血管部位的可用性有限
- Infusion therapy interrupted / 输液治疗中断
- Potential for complications / 可能出现并发症
  - infectious, thrombotic and mechanical / 感染、形成血栓和机械
- 57%-67% of patients experience adverse physical and psychological symptoms from catheter R&R* / 57%-67% 的患者会因导管R&R而出现不良的生理和心理症状*
- High cost / 高成本
  - ~$10K cost of R&R procedure / R&R流程成本约为$1万
  - $46K-$65K cost of CRBSI/CLABSI episode / CRBSI/CLABSI的费用为$4.6万- $6.5万



* Chaftari, AM et al,. Unnecessary Removal of CVCs in Cancer Patients with CRBSI: Impact on Symptom Burden. Poster presentation at ID Week 2017, Infectious Diseases Society of America (IDSA)Oct 04 - 08, 2017

POTENTIAL GOLD STANDARD IN CLABSI TREATMENT
CLABSI治疗的潜在黄金标准

Mino-Lok addresses the complications, discomfort and cost of CVC removal and replacement / Mino-Lok解决了并发症、不适和CVC移除和替换产生的高成本问题

- ✓ Limited duration IV therapy / 有限时间静脉治疗

× 5-7 DAYS





- ✓ Limits disruption of infusion therapy / 限制输液治疗的中断
- ✓ Ease of Administration: Locking a catheter is a well-known standard operating procedure / 便于管理： 封锁导管是众所周知的标准操作程序
- ✓ Not flushed into the venous system / 没有进入静脉系统
- ✓ Lowers risks to patient / 对患者来说风险降低
- ✓ Lower cost alternative: significantly less than removal and replacement / 成本更低的替代方案：大大低于移除和替换成本

MINO-LOK PHASE 3 PIVOTAL TRIAL UNDERWAY
正在进行MINO-LOK三期关键试验

Multi-center, randomized, open label, blinded assessor, active control superiority study /多中心、随机、开放标签、盲法评估、主动控制优势研究

Patients with catheter-related blood stream infections (CRBSI) randomized /导管相关血流感染（CRBSI）患者随机分组

ACTIVE ARM: Mino-Lok Solution / 主动管理组：Mino-Lok液体

CONTROL ARM: / 控制组： Antibiotic Lock + standard of care antibiotic (site specific) / 抗生素封管 + 标准治疗抗生素（特定场所）

6 weeks / 6周

92 catheter failure events required for Trial Completion / 试验完成需要92个导管失败事件

- Primary Endpoint: Comparison of Time to Catheter Failure Event (TOC = 6 weeks) / 主要终点：导管失败事件发生时间比较（ TOC = 6周）
- Interim Analyses: DMC recommended proceeding with trial without modification following 3 reviews / 中期分析：三次审查后，DMC 建议不加修改地继续进行试验
- Clinical trial sites in the U.S. and India / 临床试验地点在美国和印度

IP & REGULATORY PROTECTIONS / 知识产权和监管保护

Robust intellectual property portfolio with protection through 2036 / 强大的知识产权组合，保护期到2036年

Qualified Infectious Disease Product (US) / 合格传染病产品（美国）

- Priority Review reduces NDA review time from 12 to 6 months / 优先审查将NDA审查时间从12个月减少到6个月
- Additional 5 years of market exclusivity upon approval, combined with Hatch-Waxman / 获得批准后，结合 Hatch-Waxman 法案，可获得额外 5 年的市场独占期

Fast Track Designation (US) / 快速通道资格（美国）

- Expedites review of drugs which treat a serious or life-threatening condition and fills an unmet medical need / 加快审查治疗严重或危及生命的疾病并满足未满足医疗需求的药物
- Rolling review allows for completed sections of the New Drug Application (NDA) to be submitted when ready / 滚动审查允许在准备就绪时提交新药申请 (NDA) 的完整部分

Supplementary Protection Certificate (EU) / 补充保护证书（欧盟）

- Extends patent protection up to 5 years / 专利保护期最高延长五年

LYMPHIR (I/ONTAK, E7777)

LYMPHIR LICENSING AND FDA PATHWAY / LYMPHIR许可及FDA路径

- September 2021 — Citius acquired the exclusive license to Eisai's E7777 (LYMPHIR) / 2021年9月 Citius收购卫材的E7777 (LYMPHIR) 的独家授权
- December 2021 — Phase 3 clinical trial completed / 2021年12月 完成三期临床试验
- September 2022 — Citius submitted a BLA for E7777 (LYMPHIR) / 2022年9月 Citius提交E7777 (LYMPHIR)的BLA
- July 2023 — FDA issued complete response letter (CRL); / 2023年7月 FDA发布完整回应函(CRL) Citius planning resubmission with remediation efforts underway / Citius计划重新提交，正在进行修复



WHAT IS CUTANEOUS T-CELL LYMPHOMA (CTCL)?
什么是皮肤 T 细胞淋巴瘤(CTCL)?

Considered to be incurable, CTCL is a general term for T-cell lymphoma that involve the skin, but may also involve the blood, lymph nodes, and internal organs / CTCL被认为是不治之症，它是涉及皮肤的T细胞淋巴瘤的统称，也可能涉及血液、淋巴结和内脏器官

CTCL accounts for approximately 4% of all non-Hodgkin lymphoma (NHL)* / CTCL约占所有非霍奇金淋巴瘤（NHL）的4%*

More prevalent in men than women and usually appears in patients in their 50s and 60s / 男性发病率高于女性，通常出现在五六十岁的患者中





Plaque Stage / 斑块阶段



Tumor Stage / 肿瘤阶段

Source: Company estimates. / 来源：公司预期

DIFFERENTIATED MECHANISM OF ACTION (MOA)
差异化的作用机制(MOA)

LYMPHIR's differentiated mechanism of action supports two therapeutic effects /LYMPHIR的差异化作用机制支持两种治疗效果

Targets Malignant Cells / 靶向恶性细胞

- Binds to IL-2 receptors to deliver diphtheria toxin, killing tumor cells directly / 与 IL-2 受体结合，释放白喉毒素，直接杀死肿瘤细胞

Eliminates Immunosuppressive Tregs / 消除免疫抑制性调节性T细胞

- Reduces number of Treg cells, subsequently enhancing anti-tumor immunity / 减少调节性T细胞的数量，从而增强抗肿瘤免疫力

COMPETITIVE LANDSCAPE / 竞争格局

- Since CTCL treatments are non-curative and often have a limited duration of response and/or are discontinued early, patients are put on multiple alternate therapies / 由于 CTCL 治疗是非根治性的，通常反应持续时间有限和/或提前终止，因此患者需要接受多种替代疗法
- LYMPHIR's differentiated MOA reinforces rationale for inclusion among the current core therapeutic options in the U.S. market / LYMPHIR 的差异化 MOA 增强了将其纳入美国市场现有核心治疗方案的理由

CITIUS PHARMA

LYMPHIR (E7777)
(denileukin diftitox)

Differentiated MOA targets IL-2 receptor / 差异化MOA靶向IL-2受体

Potential to be additive to market / 有望成为市场的增量

Brand / 品牌	Marketed By / 营销方	MOA
ADCETRIS® brentuximab vedotin for injection	Seagen®	CD30 antigen directed / CD30抗原导向
POTELIGEO® (mogamulizumab-kpkc)	KYOWA KIRIN	CCR4 targeted / 靶向 CCR4
ISTODAX® (romidepsin) for injection 10-MG SINGLE-USE VIAL	Bristol Myers Squibb™	HDAC inhibitor / HDAC 抑制剂

LYMPHIR™ expected to be included among core targeted systemic therapy options / 预计LYMPHIR™将成为核心靶向系统疗法之一

MARKET OPPORTUNITY / 市场机会

- Estimated U.S. market size for LYMPHIR in CTCL is $300-$400+ million / 预计LYMPHIR在美国的CTCL的市场规模为$3亿- $4亿以上
- Key growth drivers expected to increase overall market size and facilitate market penetration / 主要增长动力预计将扩大整体市场规模并促进市场渗透
  - Evolving treatment paradigm; incremental therapeutic option for pre-treated patients / 不断发展的治疗范式；预处理患者的增量治疗选择
  - Historically, market growth has followed introduction of new therapeutics / 从历史上看，市场增长是随着新疗法的推出而出现的
  - Competitively priced / 有竞争力的定价

Systemic CTCL Therapies / 系统的CTCL疗法



EST. ADDRESSABLE MARKET / 预期目标市场

$300-$400+M / $3亿-$4亿以上

LYMPHIR PHASE 3 TRIAL (STUDY 302): COMPLETED / 已完成LYMPHIR三期临床试验（302研究）

Pivotal, multicenter, open-label, single-arm study of LYMPHIR in subjects with persistent or recurrent CTCL / 针对持续或复发CTCL受试者的 LYMPHIR 多中心、开放标签、单臂关键研究

All subjects were diagnosed with Mycosis Fungoides or Sézary Syndrome, with tumors assessed as positive for expression of the CD25 subunit of the IL-2 receptor / 所有受试者均被诊断为真菌病或塞扎里综合征，其肿瘤被评估为 IL-2 受体 CD25 亚基表达阳性



- A total of 69 subjects with Stage I-III persistent or recurrent CTCL from the Lead-In and Main Studies were included in the Primary Efficacy Analysis Set / 共有69名来自先导研究和主要研究的I-III期持续性或复发性CTCL受试者被纳入主要疗效分析组

PRECLINICAL DATA SIGNALS POTENTIAL IN I/O
临床前数据表明，在免疫肿瘤学领域也有潜力

Preclinical study: adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall survival compared to monotherapy / 临床前研究：与单一疗法相比，在抗PD-1疗法中加入LYMPHIR可增强抗肿瘤活性并提高总生存率

Published in Peer-Reviewed
***Frontiers in Immunology*[1] / 发表于同行评议的**
***《免疫学前沿》*[1]**



frontiers About us All journals All articles Submit your research

Frontiers in Immunology Sections Articles Research Topics Editorial Board About journal

ORIGINAL RESEARCH article

Front. Immunol., 27 October 2023
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1268979

This article is part of the Research Topic
Targeting Regulatory Cells in Cancer: Old and New Approaches in Immunotherapy
View all Articles

Targeting regulatory T cells by E7777 enhances CD8 T-cell–mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models

Haider S. Mahdi[1*] Mary Woodall-Jappe[2] Preeti Singh[3] Myron S. Czuczman[3]

[1] Department of Obstetrics, Gynecology & Reproductive Sciences, Magee-Womens Hospital, University of Pittsburgh, Pittsburgh, PA, United States
[2] MWJ Scientific Consulting, Ipswich, MA, United States
[3] Clinical Development and Medical Affairs, Citius Pharmaceuticals, Inc., Cranford, NJ, United States

Introduction: Regulatory T cell (Treg)-targeting cancer immunotherapy aims to transiently deplete Treg cells in the tumor microenvironment, without affecting effector T cells (Teff), thus both enhancing anti-tumor activity and avoiding autoimmunity. This study evaluated whether adding E7777 (a new formulation of denileukin diftitox [DD]) improved the efficacy of anti-PD-1 antibody therapy. DD is a recombinant protein containing the hydrophobic and catalytic portions of diphtheria toxin fused to full-length human IL-2. E7777 has the same amino acid sequence and brief circulatory half-life as DD, but with greater purity and potency.

Methods: Subcutaneous syngeneic murine solid tumor models (colon cancer CT-26 and liver cancer H22) were used to evaluate safety, efficacy, and overall survival with E7777 and anti-PD-1 antibodies, each administered as monotherapy or in concurrent or sequential combination. In Experiment 1, treatments were compared to assess anti-tumor activity at various time points, with tumors excised and dissociated and tumor

Key Study Results / 主要研究结果

- LYMPHIR + anti-PD-1
  - Demonstrated significant anti-tumor activity, and / 显示了很高的抗肿瘤活性，并且
  - Consistently targeted and transiently depleted Tregs / 持续靶向和短暂耗尽调节性T细胞
- Combination treatment was more effective than monotherapy / 联合治疗比单药治疗更有效
- Combination therapy was well-tolerated and significantly enhanced long-term survival in solid tumor-bearing animals / 联合疗法耐受性良好，能显著提高实体瘤动物的长期存活率
- Informed design of investigator-initiated trials at Univ. of Minnesota and University of Pittsburgh / 明尼苏达大学和匹兹堡大学研究人员发起的试验的知情设计

1.Mahdi, H. Woodall-Jappe, M., Singh, P., Czuczman, S., Targeting Regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models. *Frontiers in Immunology.* (Published online ahead of print, 2023 October 27).

OPPORTUNITIES FOR GROWTH / 发展机会

PTCL expanded indication potential / PTCL扩大了适应症潜力

- Eisai's E7777 is already approved for the treatment of Peripheral T-Cell Lymphoma (PTCL) in Japan (Remitoro®) / 卫材的 E7777 (Remitoro®)已在日本获准用于治疗外周 T 细胞淋巴瘤 (PTCL)
- Would require clinical trial in U.S. designed as a single-arm pivotal study / 需要在美国进行临床试验，设计为单臂关键性研究

Upside opportunity in immuno-oncology / 在免疫肿瘤领域的潜力机会

- Two investigator-initiated trials are underway to evaluate LYMPHIR for potential as an immuno-oncology combination therapy / 目前正在进行两项由研究者发起的试验，以评估 LYMPHIR 作为免疫肿瘤联合疗法的潜力

LYMPHIR in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors (NCT05200559) / LYMPHIR与KEYTRUDA®联合使用治疗复发性或转移性实体瘤患者 (NCT05200559)	Collaboration with the University of Pittsburgh / 与匹兹堡大学合作
LYMPHIR given prior to lymphodepletion chemotherapy and CAR T therapies for the treatment of relapsed/refractory B-cell lymphomas considered at a high risk for failure from KYMRIAH® alone (NCT04855253) / 在淋巴清除化疗和CAR T疗法之前使用LYMPHIR，用于治疗被认为单用KYMRIAH®治疗失败风险较高的复发/难治性B细胞淋巴瘤(NCT04855253)	Collaboration with the University of Minnesota / 与明尼苏达大学合作

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. / KEYTRUDA® 是默沙东的注册商标，默沙东是默克公司的子公司，位于美国新泽西州Kenilworth
KYMRIAH® is a registered trademark of Novartis AG, Basel, Switzerland / KYMRIAH® 是瑞士巴塞尔的诺华公司的注册商标

HALO-LIDO

Halobetasol/Lidocaine

HALO-LIDO: PHASE 2B TRIAL OVERVIEW / 2B期临床试验概述

Potentially the first FDA-approved prescription product to treat hemorrhoids in the US / 有可能成为美国 FDA 批准的首个治疗痔疮的处方产品

- Based on the results of Phase 2 trial in 240 patients, CTXR elected to use highly potent steroid Halobetasol propionate (HBP), maintained Lidocaine HCl (LH) and developed 10 prototype formulations / 根据 240 名患者的二期试验结果，CTXR 选择使用强效类固醇卤贝他索丙酸酯(HBP)，保留盐酸利多卡因 (LH)，并开发了 10 种原型配方

- A cream formulation containing novel excipient selected for Phase 2b study / 一种含有新型赋形剂的膏霜配方被选中进行2b期研究

- Phase 2b enrollment completed April 2023 / 2023年4月完成2b期试验的患者招募
  - 5 cohorts of 60 subjects each / 5组，每组60人
  - Primary endpoint: reduction in hemorrhoidal symptoms / 主要终点：减轻痔疮症状
  - Subjects to self-report using proprietary mobile app / 受试者使用专有移动应用程序进行自我报告

- Positive Phase 2b results / 2b期试验获得积极结果
  - CITI-002 provides a meaningful reduction in symptom severity when compared to individual components alone / 与单个成分相比，CITI-002 可有效减轻症状的严重程度
  - Dose for Phase 3 trial selected; Citius to schedule end of Phase 2 meeting with the FDA / 三期试验的剂量已选定；Citius 将与 FDA 举行二期试验结束会议
  - Trial validates Patient Reported Outcome (PRO) instrument developed to support a pivotal Phase 3 study / 试验验证了为支持关键性三期研究而开发的患者报告结果 (PRO) 工具

10+ MILLION / 1000万以上

Patients report symptoms of hemorrhoidal disease and 1/3 seek physician treatment [1] / 患者报告有痔疮症状，1/3 的患者寻求医生治疗[1]

1. Source / 来源: https://www.mayoclinic.org/medical-professionals/digestive-diseases/news/hemorrhoidal-disease-diagnosis-and-management/mac-20430067

SUMMARY / 总结

WHY INVEST? WHY NOW? / 为何现在投资？

- **Diversified late-stage pipeline with near term catalysts / 多元化的后期产品管线，近期有催化剂**

MINO-LOK
Salvage CVCs / 抢救CVCs

- Phase 3 trial nearing completion / 三期临床试验接近完成
- Topline results anticipated first half of 2024 / 预计2024年上半年发布顶线结果

LYMPHIR
Treat CTCL, PTCL, I/O / 治疗CTCL、PTCL、I/O

- CRL remediation underway / 正在进行CRL补救
- Early-2024 resubmission planned / 计划2024年初重新提交申请

HALO-LIDO
Rx therapy for hemorrhoids / 痔疮的处方疗法

- Prep for end of Phase 2 meeting with FDA / 准备与FDA召开二期临床试验结束会议
- Potential for monetization through partnerships / 有潜力通过合作变现

- **Healthy Financial Platform with cash runway through August 2024 / 健康的财务平台，现金可用至2024年8月**
  - $33.3 M cash as of 6/30/23 / 截止2023年6月30日有$3330万现金
  - $26.5 M invested by founders / 创始人投资了$2650万

PRINCIPAL INSIDER SHAREHOLDERS /主要内部股东(1)	
LEONARD MAZUR	11.4%
MYRON HOLUBIAK	2.7%

CURRENT CAPITALIZATION / 当前市值 (2)	SHARES / 股数	% OF FULLY DILUTED / 占完全摊薄后股数的比例
BASIC SHARES OUTSTANDING / 发行在外基本股	158,857,798	71.2%
WARRANTS / 认股权证	50,923,819	22.8%
OPTIONS / 期权	13,380,171	6.0%
FULLY DILUTED SHARES OUTSTANDING / 完全摊薄后发行在外股票	**223,161,788**	**100%**

(1) Beneficial stock ownership as calculated under rules of the SEC as filed with the Citius Def 14 A Proxy Statement in December 2022 and based on 158,857,798 shares outstanding as of June 30, 2023. / 根据 2022 年 12 月提交 Citius Def 14 A 委托书的美国证券交易委员会规则计算的实际持股量，基于截至 2023 年 6 月 30 日的 158,857,798 股发行在外股票

(2) As of June 30, 2023. / 截止2023年6月30日